Response rates (SR-6) to interferon alfa (IFN) therapy in patients with chronic hepatitis B according to hepatitis B virus (HBV) genotype
| Genotype A | Genotype D | p Value | |
|---|---|---|---|
| SR-6, sustained response six months post treatment; ETR, end of treatment response; HBeAg, hepatitis B e antigen. | |||
| All patients | |||
| n | 78 | 66 | |
| Cumulative IFN dose (MU) | 418 (21) | 447 (20) | NS |
| Treatment duration (months) | 6.7 | 6.2 | NS |
| ETR (%) | 59 | 46 | NS |
| Relapse (% of ETR) | 17 | 43 | 0.02 |
| SR-6 (%) | 49 | 26 | 0.005 |
| HBeAg positive | |||
| n | 61 | 38 | |
| Cumulative IFN dose (MU) | 395 (21) | 442 (29) | NS |
| Treatment duration (months) | 5.8 (0.2) | 6.7 (0.4) | 0.05 |
| ETR (%) | 53 | 29 | 0.02 |
| Relapse (% of ETR) | 13 | 18 | NS |
| SR-6 (%) | 46 | 24 | 0.03 |
| HBeAg negative | |||
| n | 17 | 28 | |
| Cumulative IFN dose (MU) | 502 (54) | 455 (27) | NS |
| Treatment duration (months) | 7.6 (0.8) | 6.7 (0.4) | NS |
| ETR (%) | 82 | 68 | NS |
| Relapse (% of ETR) | 29 | 58 | NS |
| SR-6 (%) | 59 | 29 | 0.05 |